Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Not one, but two positive news items out today

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Oct 24, 2023 5:53pm

217 Views

Post# 35699118

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Not one, but two positive news items out today

Won't argue with all of this but Matt stated in his latest Fireside that the delay will be due to the additional trial arm with Folfirinix that Pancan offered and paid for. This requires amendments to the paperwork and agreements they had already been working through.

I wasn't happy with the missed deadline but we've been offered a 2 arm trial against the current standard of care. This is a bigger deal than most here seem to realize.

<< Previous

Bullboard Posts

Next >>

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project